Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Tailored diuretic treatment for patients with acute heart failure

Official title: TAILOR-AHF: Randomized Trial Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients

Run by Zuyderland Medisch Centrum · NCT06092437 · Data updated 2026-11-12

This study tests if a personalized diuretic treatment based on urine sodium levels can help people with acute heart failure feel better faster than standard care.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment556 (estimated)
SponsorZuyderland Medisch Centrum
Academic / other
Locations2 sites (Heerlen, Limburg and 1 other locations)
StatusRecruiting
StartedFebruary 27, 2023
Main results expectedJune 27, 2026
Study endsAugust 27, 2026
Registry record updatedApril 13, 2026
Trial IDNCT06092437 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old diagnosed with acutely decompensated heart failure requiring intravenous diuretics.

Probably not a fit

Patients with terminal renal insufficiency or those requiring intensive care upon admission may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates a tailored diuretic algorithm based on urinary sodium levels in patients with acutely decompensated heart failure. The study aims to determine if this personalized approach can lead to faster and more complete decongestion compared to standard care, ultimately improving patient outcomes. Participants will be randomly assigned to receive either the tailored treatment or usual care, with their responses monitored to assess effectiveness and safety. The trial is designed to provide evidence for implementing urinary sodium as a biomarker in diuretic therapy.

Why it matters

Potential benefit: If successful, this approach could lead to improved survival rates and reduced heart failure events for patients with acute heart failure.

How similar studies have gone: While the use of urinary sodium as a biomarker is promising, this specific tailored approach is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 18 years;
* HF (HFrEF, HFmrEF or HFpEF) diagnosed according to the 2021 HF Guidelines of the European Society of Cardiology \[5\];
* Presentation with AHF meaning at least one symptom (dyspnea, orthopnea, or edema) and one sign (rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography) of AHF;
* An elevated NT-proBNP \>300pg/ml;
* Requiring the need for iv diuretics.

Exclusion Criteria:

* Terminal renal insufficiency defined as: dialysis patients or eGFR (estimated glomerular filtration rate) \< 10 mL/min/1.73 m2;
* Patients included in other investigational studies regarding heart failure.
* Presentation with cardiogenic shock or respiratory insufficiency or another reason requiring admission to the intensive care unit upon admission (IC transfer later in the hospitalization is not an exclusion).

Where it's running

  • Zuyderland MC
    Heerlen, Limburg, Netherlands
    Recruiting
  • Amphia ziekenhuis
    Breda, North Brabant, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.